Armour/Miles Factor VIII
Rhone-Poulenc Rorer subsidiary will market Miles' recombinant Factor VIII for the treatment of hemophilia A. Under the terms of a January 1993 settlement of a patent dispute between the two companies ("The Pink Sheet" Feb. 8, 1993, In Brief), Miles will supply Armour with rFVIII, which Armour will sell under the name Helixate, which will be available in the second half of 1994. Armour's DDAVP nasal spray for mild hemophilia and von Willebrand's disease was cleared by FDA on March 7
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth